Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of nine systematic review(s)/meta-analysis(es). ^[1-9]
• The studies focused on chronic lymphocytic leukemia (CLL) patients with advanced age and/or comorbidities, including high-risk genetic subgroups such as TP53 aberrations, IGHV unmutated status, and 11q deletion, with findings indicating that patients with unmutated IGHV status had better progression-free survival (PFS) with acalabrutinib plus obinutuzumab compared to venetoclax plus obinutuzumab.
• In patients with B-cell non-Hodgkin lymphomas (B-NHL), the studies included those with CD20-positive B-NHL, showing that obinutuzumab significantly improved PFS but had a higher incidence of adverse events compared to rituximab.
• Zanubrutinib was identified as the safest treatment option for CLL patients with advanced age and/or comorbidities, followed by venetoclax-obinutuzumab, while Bruton's tyrosine kinase inhibitor (BTKi) monotherapies demonstrated more favorable safety profiles regarding hematological adverse events (AEs).
• Obinutuzumab was associated with increased incidences of serious AEs, including an odds ratio (OR) of 1.29 for serious AEs, a relative risk (RR) of 2.8 for thrombocytopenia, infusion-related reactions, and a RR of 1.65 for cardiac events compared to rituximab, indicating higher toxicity in obinutuzumab-based regimens.